Drug Development Pharma - May 13, 2014
Kancera applies for new patent
The company has registered a patent application for new substances for cancer treatment that selectively inhibit the enzyme HDAC6. The new patent application is based on HDAC6 inhibitors ability to affect mechanisms both inside of and outside of the cell nucleus. According to an announcement from the company it has been proven that HDAC6 has […]
Drug development - January 23, 2014
Kancera starts ROR study
The company has announced that it is initiating the development of a vaccine directed against ROR. Kancera’s strategy is, according to the Karolinska Institutet Science Park company, to use its future small-molecule ROR inhibitors as a first line treatment for the disease and thereafter follow with a prophylactic ROR vaccine to prevent relapse. The initiative is motivated by […]
